La Jolla Pharma's drug improves kidney function in mid-stage study

March 10 Mon Mar 10, 2014 4:31pm EDT

March 10 (Reuters) - La Jolla Pharmaceutical Co said its experimental drug to treat chronic kidney disease met the main goal of improving kidney function in a mid-stage study.

The company said a lower dose of the drug, codenamed GCS-100, showed an increase in the rate of blood filtering through the kidneys, compared with a placebo.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.